Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin)
Yıl: 2023 Cilt: 7 Sayı: 1 Sayfa Aralığı: 35 - 39 Metin Dili: Türkçe DOI: 10.37783/CRJ-0337 İndeks Tarihi: 17-05-2023
Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin)
Öz: Göz ve göz çevresi cerrahisi sonrası retinal damar tıkanıklığı ve vasküler yatak hasarı nadir fakat oldukça ciddi bir komplikasyondur. Kardiyovasküler hastalık hikayesi, retrobulber enjeksiyon, perioperatif yüksek göz içi basıncı ve ilaç toksisitesi olası nedensel faktörler olarak bildirilmişlerdir. Katarakt cerrahisi sırasında intrakamaral antibiyotik uygulaması ise dünyada neredeyse tüm oftalmologlar tarafından benimsenmiş ve rutin uygulanmaya alınmıştır. İntravitreal antimikrobiyal uygulama göz içi enfeksiyonlarının tedavisini ilerletmiştir. Kan-oküler bariyerleri baypas edebilmek, yüksek ilaç konsantrasyonlarının minimum sistemik absorpsiyon ile doğrudan arka segmente iletilmesine izin verir. Bununla birlikte, bazı antimikrobiyal ilaçların terapötik ve toksik dozları arasındaki fark dar bir konsantrasyon aralığına düştüğü için intravitreal tedavi oküler toksisite riskleri ile ilişkilendirilebilir.
Anahtar Kelime: Medications Damaging Vascular Bed or Causing Microvasculopathy / Occlusion-3: Pathogenesis, Diagnosis, and Treatment (Intraocular Gentamicin, Tobramycin, Amikacin, Vancomycin, Moxifloxacin)
Öz: Retinal vascular occlusion and vascular bed injury are rare but serious complications after eye and periocular surgery. History of cardiovascular disease, retrobulbar injection, perioperative high intraocular pressure, and drug toxicity have been reported as possible causative factors. Intracameral antibiotic administration during cataract surgery has been adopted by almost all ophthalmologists in the world and has been routinely applied. Intravitreal antimicrobial administration has advanced the treatment of intraocular infections. Being able to bypass the blood-ocular barriers allows high drug concentrations to be delivered directly to the posterior segment with minimal systemic absorption. However, intravitreal therapy may be associated with risks of ocular toxicity, as the difference between therapeutic and toxic doses of some antimicrobial drugs falls within a narrow concentration range.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Bibliyografik
- 1. Fischer C, Bruggemann A, Hager A, Callizo Planas J, Roider J, Hoerauf H. Vascular occlusions following ocular surgical procedures: a clinical observation of vascular complications after ocular surgery. J Ophthalmol. 2017; (503):1-6.
- 2. Tappeiner C, Garweg JG. Retinal vascular occlusion after vitrectomy with retrobulbar anesthesia-observational case series and survey of literature. Graefes Arch Clin Exp Ophthalmol. 2011;249(12):1831–5.
- 3. Russell JF, Scott NL, Haddock LJ, Eaton AM, Flynn HW. Central retinal artery occlusion on postoperative day one after vitreoretinal surgery. Am J Ophthalmol. Case Rep. 2018;12:93–6.
- 4. Packer M, Chang DF, Dewey SH, Lİttle BC, Mamalis N, Oetting TA et al. Prevention, diagnosis, and management of acute postoperative bacterial endophthalmitis. J Cataract Refract Surg. 2011;37(2):1699-1714.
- 5. Taban M, Behrens A, Newcomb RL, Nobe MY, Saedi G, Sweet PM et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol. 2005;123(5):613- 620.
- 6. Endophthalmitis Study Group ESoC, Refractive S. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33(6):978-988.
- 7. Garcia-Saenz MC, Arias-Puente A, Rodriguez-Caravaca G, Banuelos JB. Effectiveness of intracameral cefuroxime in preventing endophthalmitis aftercataract surgery Ten-year comparative study. J Cataract Refract Surg. 2010;36(2):203-207.
- 8. Matsuura K, Miyoshi T, Suto C, Akura J, Inoue Y. Efficacy and safety pofprophylactic intracameral moxifloxacin injection in Japan. J Cataract Refract Surg. 2013;39(11):1702-1706.
- 9. Anijeet DR, Palimar P, Peckar CO. Intracameral vancomycin following cataract surgery: An eleven-year study. Clin Ophthalmol. 2010;26(4):321-326.
- 10. Cakir B, Celik E, Aksoy NO, Bursalı Ö, Uçak T, Bozkurt E et al. Toxic anterior segment syndrome after uncomplicated cataract surgery possibly associated with intracamaral use of cefuroxime. Clin Ophthalmol. 2015;17(9):493-497.
- 11. Sakarya Y, Sakarya R. Cefuroxime dilution error. Eur J Ophthalmol. 2010;20(2):460-461.
- 12. Chang DF, Braga-Mele R, Mamalis N, Masket S, Miller KM, Nichamin L et al. Prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2007 ASCRS member survey. J Cataract Refract Surg. 2007;33(10):1801-1805.
- 13. Braga-Mele R, Chang DF, Henderson BA, Mamalis N, Talley-Rostrov A, Vasavada A et al. Intracameral antibiotics: Safety, efficacy, and preparation. J Cataract Refract Surg. 2014;40(12):2134-2142.
- 14. Witkin AJ, Shah AR, Engstrom RE, Kron-Krey MM, Baumal CR, Johnson MM et al. Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin. Ophthalmology. 2015;122(7):1438–1451
- 15. Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. 2003;16(3):430 – 450.
- 16. Thomas T, Galiani D, Brod RD. Gentamicin and other antibiotic toxicity. Ophthalmol Clin North Am. 2001;14(4):611– 624
- 17. Schacht J. Biochemical basis of aminoglycoside ototoxicity. Otolaryngol Clin North Am. 1993;26(5):845– 856.
- 18. Swan S. Aminoglycoside nephrotoxicity. Semin Nephrol. 1997;17(1): 27–33.
- 19. Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv. Drug Deliv Rev 1995;16(1):107-23
- 20. Novack GD, Robin AL. Ocular pharmacology. J Clin Pharmacol. 2016;56(5): 517–527.
- 21. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 2008;27(6): 622–647.
- 22. Myles M, Neumann D, Hill J. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev. 2005; 57(14): 2063–2079.
- 23. Jager RD, Aiello LP, Patel SC, Cunningham ET . Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5): 676–698)
- 24. Judson PH. Aminoglycoside macular toxicity after subconjunctival injection. Arch Ophthalmol. 1989;107(9):1282–1283.
- 25. Conway BP, Campochiaro PA. Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin. Arch Ophthalmol. 1986;104(3):367–371.
- 26. Cardascia N, Boscia F, Furino C, Sborgia L. Gentamicin-induced macular infarction in transconjunctival sutureless 25-gauge vitrectomy. Int Ophthalmol. 2008;28(5):383–5.
- 27. Brouzas D, Moschos MM, Koutsandrea C, Davou S, Georgalas I. Gentamicin-induced macular toxicity in 25- gauge sutureless vitrectomy. Cutan Ocul Toxicol. 2013;32(3):258–9.
- 28. Heath Jeffery RC, Bowden FJ, Essex RW. Subconjunctival gentamicin- induced macular toxicity following sutureless 25-gauge vitrectomy. Clin Exp Ophthalmol. 2017;45(3):301–4.
- 29. Conway BP, Tabatabay CA, Campochiaro PA, D’Amico DJ, Hanninen LA, Kenyon KR. Gentamicin toxicity in the primate retina. Arch Ophthalmol. 1989;107(1):107–12
- 30. Hancock HA, Guidry C, Read RW, Ready EL, Kraft TW. Acute Aminoglycoside Retinal Toxicity In Vivo and In Vitro Investigati ve Ophthalmology & Visual Science. 2005;46(12): 4804-4808.
- 31. Harris A, Ciulla TA, Chung HS, Martin BJ. Regulation of retinal and optic nerve blood flow. Arch Ophthalmol. 1998;116(11):1491– 1495.
- 32. Snider JD, Cohen HB, Chenoweth RG. Acute ischemic retinopathy secondary to intraocular injection of gentamicin. In: Ryan SJ, Dawson AK, Little HL, editors. Retinal diseases. Orlando, FL: Grune and Stratton, 1985:227-32.
- 33. D’Amico DJ, Libert J, Kenyon KR, Hanninen LA, Caspers-Velut L. Retinal toxicity of intravitreal gentamicin. An electron microscopic study. Invest Ophthalmol Vis Sci. 1984;25(5):564 –572.
- 34. Oum BS, D’Amico DJ, Kwak HW, Wong KW. Intravitreal antibiotic therapy with vancomycin and aminoglycoside: examination of the retinal toxicity of repetitive injections after vitreous and lens surgery. Graefes Arch Clin Exp Ophthalmol. 1992;230(1):56–61.
- 35. D’Amico DJ, Caspers-Velu L, Libert J, Shanks E, Schrooyen M, Hanninen LA, Kenyon KR: Comparative toxicity of intravitreal aminoglycoside antibiotics. Am J Ophthalmol. 1985;100(2):264– 275.
- 36. Campochiaro PA, Lim JI; The Aminoglycoside Toxicity Study Group. Aminoglycoside toxicity in the treatment of endophthalmitis. Arch Ophthalmol. 1994;112(1):48–53.
- 37. Chang DF, Braga-Mele R, Henderson BA, Mamalis N, Vasavada A. Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2014 ASCRS member survey. J Cataract Refract Surg. 2015;41(6):1300-1305.
- 38. Behndig A, Cochener B, Guell JL, Kodjikian L, Mencucci R, Nuijts RMMA, et al. Endophthalmitis prophylaxis in cataract surgery: overview of current practice patterns in 9 European countries. J Cataract Refract Surg. 2013;39(9):1421-1431.
- 39. Nicholson LB, Kim BT, Jardon J, et al. Severe bilateral ischemic retinal vasculitis following cataract surgery. Ophthalmic Surg Lasers Imaging Retina. 2014;45(4): 338-342.
- 40. Patel SB, Reddy NK, He Y-G. Toxic posterior segment syndrome after dropless cataract surgery with compounded triamcinolone- moxifloxacin. Retina. 2020;40(3):446–455.
- 41. Gonul S, Eker S. Unilateral Acute Iris Transillumination Syndrome following Uneventful Phacoemulsification Surgery with Intracameral Moxifloxacin. Ocul Immunol Inflamm. 2021 May 18:1-4. doi: 10.1080/09273948.2021.1916042. Epub ahead of print.
- 42. Marchiori E, Zanetti G, Mano CM, Hochhegger B, Irion KL. Talc-induced pulmonary granulomatosis or septic pulmonary embolism? A diagnostic challenge. Ann Thorac Surg. 2010; 90(1):362–363.
- 43. Bourgeois N, Chavant F, Lafay-Chebassier C, Leveziel N, Pérault- Pochat MC. Drugs and retinal disorders: a case/noncase study in the French pharmacovigilance database. Therapie. 2016; 71(4):365–374.
- 44. Medhat E, Esmat G, Hamza E, Aziz AA, Fathalah WF, Darweesh SK et al. Ophthalmological side effects of interferon therapy of chronic hepatitis C. Hepatobiliary Surg Nutr. 2016; 5(3):209–216.
- 45. McDonald HR, Schatz H, Allen AW, Chenoweth RG, Cohen HB, Crawford JB, et al. Retinal toxicity secondary to intraocular gentamicin injection. Ophthalmology. 1986;93(7):871– 876.
- 46. Cardascia N, Boscia F, Furino C, Sborgia L. Gentamicin-induced macular infarction in transconjunctival sutureless 25-gauge vitrectomy. Int Ophthalmol. 2008 Oct;28(5):383–5.
- 47. Brouzas D, Moschos MM, Koutsandrea C, Davou S, Georgalas I. Gentamicin-induced macular toxicity in 25- gauge sutureless vitrectomy. Cutan Ocul Toxicol. 2013 Sep;32(3):258–9.
- 48. Heath Jeffery RC, Bowden FJ, Essex RW. Subconjunctival gentamicin- induced macular toxicity following sutureless 25-gauge vitrectomy. Clin Exp Ophthalmol. 2017 Apr;45(3):301–4.
- 49. Witkin AJ, Chang DF, Jumper JM, Charles S, Eliott D, Hoffman RS, et all. Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis:Clinical Characteristics of 36 Eyes. Ophthalmology. 2017 May;124(5):583-595.
- 50. Muraoa F, Kinoshitab T, Katomea T, Sanoa H, Nikia M, Mitamuraa Y. Suspected Gentamicin-Induced Retinal Vascular Occlusion after Vitrectomy. Case Rep Ophthalmol. 2020;11(2):473–480.
| APA | KOÇKAR A, YÜZBAŞIOĞLU E (2023). Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin). , 35 - 39. 10.37783/CRJ-0337 |
| Chicago | KOÇKAR ALEV,YÜZBAŞIOĞLU ERDAL Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin). (2023): 35 - 39. 10.37783/CRJ-0337 |
| MLA | KOÇKAR ALEV,YÜZBAŞIOĞLU ERDAL Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin). , 2023, ss.35 - 39. 10.37783/CRJ-0337 |
| AMA | KOÇKAR A,YÜZBAŞIOĞLU E Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin). . 2023; 35 - 39. 10.37783/CRJ-0337 |
| Vancouver | KOÇKAR A,YÜZBAŞIOĞLU E Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin). . 2023; 35 - 39. 10.37783/CRJ-0337 |
| IEEE | KOÇKAR A,YÜZBAŞIOĞLU E "Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin)." , ss.35 - 39, 2023. 10.37783/CRJ-0337 |
| ISNAD | KOÇKAR, ALEV - YÜZBAŞIOĞLU, ERDAL. "Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin)". (2023), 35-39. https://doi.org/10.37783/CRJ-0337 |
| APA | KOÇKAR A, YÜZBAŞIOĞLU E (2023). Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin). Güncel Retina Dergisi, 7(1), 35 - 39. 10.37783/CRJ-0337 |
| Chicago | KOÇKAR ALEV,YÜZBAŞIOĞLU ERDAL Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin). Güncel Retina Dergisi 7, no.1 (2023): 35 - 39. 10.37783/CRJ-0337 |
| MLA | KOÇKAR ALEV,YÜZBAŞIOĞLU ERDAL Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin). Güncel Retina Dergisi, vol.7, no.1, 2023, ss.35 - 39. 10.37783/CRJ-0337 |
| AMA | KOÇKAR A,YÜZBAŞIOĞLU E Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin). Güncel Retina Dergisi. 2023; 7(1): 35 - 39. 10.37783/CRJ-0337 |
| Vancouver | KOÇKAR A,YÜZBAŞIOĞLU E Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin). Güncel Retina Dergisi. 2023; 7(1): 35 - 39. 10.37783/CRJ-0337 |
| IEEE | KOÇKAR A,YÜZBAŞIOĞLU E "Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin)." Güncel Retina Dergisi, 7, ss.35 - 39, 2023. 10.37783/CRJ-0337 |
| ISNAD | KOÇKAR, ALEV - YÜZBAŞIOĞLU, ERDAL. "Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-3: Patogenez, Tanı ve Tedavi (İntraoküler Gentamisin, Tobramisin, Amikasin, Vankomisin, Moksifloksasin)". Güncel Retina Dergisi 7/1 (2023), 35-39. https://doi.org/10.37783/CRJ-0337 |
